This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GNC Holdings (GNC) Lags Q3 Earnings & Revenues, Margins Down
by Zacks Equity Research
GNC Holdings (GNC) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from the recent hurricanes and lower sales at the U.S. & Canada and manufacturing/wholesale segments.
Cardiovascular Systems (CSII) Q1 Earnings Top, Revenues Lag
by Zacks Equity Research
Cardiovascular Systems' (CSII) Q1 revenues declined year over year owing to the decline in revenues at both the segments.
Boston Scientific's (BSX) Q3 Earnings In Line, Guidance Up
by Zacks Equity Research
Despite back-to-back natural disasters, Boston Scientific managed to register strong year-over-year increase in both earnings and revenues in the third quarter on balanced growth across all segments.
McKesson (MCK) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
McKesson (MCK) reported strong second-quarter numbers owing to stable performance from Distribution Solutions business.
Bet on Driehaus Strategy With These 5 Momentum Stocks
by Zacks Equity Research
Investors with a high risk appetite might give the Driehaus strategy a thought to boost returns.
Thermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance Up
by Zacks Equity Research
On solid third-quarter performance, a favorable foreign exchange environment and the recently closed acquisition of Patheon, Thermo Fisher (TMO) has raised its full-year 2017 guidance.
LabCorp (LH) Beats Q3 Earnings Estimates, Raises Guidance
by Zacks Equity Research
Banking on strong third-quarter show and considering a gradually improving foreign exchange scenario, LabCorp (LH) increased its earlier provided 2017 outlook.
Walgreens Boots (WBA) Tops Q4 Earnings, Issues 2018 View
by Zacks Equity Research
Walgreens Boots (WBA) surpasses the Zacks Consensus Estimate for both the counts in Q4 on continued prescription growth and strength in the Retail Pharmacy USA division.
Baxter (BAX) Beats on Earnings & Sales in Q3, 2017 View Up
by Zacks Equity Research
Baxter (BAX) exited the third quarter on a solid note, courtesy of stellar performances by the company's hospital products and renal segments.
NuVasive (NUVA) Q3 Earnings Top, Revenues Lag, Guidance Cut
by Zacks Equity Research
NuVasive's robust top-line growth in Q3 was driven by strong international performance. However, U.S. sales declined on procedural volume challenges and an adverse impact of the recent natural disasters.
Accuray's (ARAY) Q1 Loss in Line, Revenues Beat Estimates
by Zacks Equity Research
Accuray (ARAY) rides high on its product and service segments in Q1.
Illumina (ILMN) Tops Q3 Earnings & Revenues, Raises Guidance
by Zacks Equity Research
Illumina (ILMN) rides high on sequencing consumables and instruments as well as microarray portfolios in Q3 earnings.
Abaxis (ABAX) Posts In-Line Earnings in Q2, Lags Revenues
by Zacks Equity Research
Abaxis (ABAX) misses the Zacks Consensus Estimate for revenues due to softness in the medical market in Q2. Weak margins are a concern as well.
Edwards Lifesciences (EW) Q3 Earnings, Sales Lag, View Intact
by Zacks Equity Research
Edwards Lifesciences (EW) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from recent natural disasters in the Caribbean and the United States.
PetMed (PETS) Tops Q2 Earnings & Sales Estimates, Margins Up
by Zacks Equity Research
The year-over-year rise in earnings of PetMed (PETS) was driven by an increase in sales and improved margins.
Bartosiak: Trading Petmed Express's (PETS) Earnings with Options
by David Bartosiak
Join Dave Bartosiak at 1:00pm Central Time on Thursday, October 20th, to see his thoughts on Petmed Express (PETS) before they report earnings with real-time options insight.
PetMed Express Optimistic on New Orders Amid Stiff Rivalry
by Zacks Equity Research
PetMed is striving to implement several strategies to revitalize its top line. Yet a highly competitive market poses threats.
3 Strong Buy Stocks to Grab on the Dip
by Ryan McQueeney
We've identified several stocks that investors should consider buying on the dip right now. All of these stocks have slumped a bit over the past four weeks, but their fortunes could be poised to change soon, as they are all currently sporting a Zacks Rank #1 (Strong Buy).
Market May Hit New Highs: 4 Retail Growth Stocks to Buy
by Zacks Equity Research
If the major indices breach their set benchmark, it is likely to boost the risk appetite of investors.
PetMed Express and Crox are Aggressive Growth Rank Buys
by Brian Bolan
PETS and CROX are profiled in this video.
Why Investors Should Buy Texas Instruments (TXN) Right Now
by Zacks Equity Research
Texas Instruments (TXN) or TI is one such technology stock which has performed well so far this year.
Amazon Extends Prime Now 1-Hour Delivery Service to Canada
by Zacks Equity Research
Amazon.com Inc.'s (AMZN) Prime membership is getting bigger and better. The online giant has added Canada to the list of countries receiving the one and two-hour delivery service, Prime Now.
Expedia Appoints Mark Okerstrom as Chief Executive Officer
by Zacks Equity Research
Expedia Inc. (EXPE) appoints Mark Okerstrom as its new chief executive officer after Dara Khosrowshahi moves to Uber.
Phibro Animal (PAHC) Beats Q4 Earnings & Sales Estimates
by Zacks Equity Research
Phibro Animal (PAHC) reported solid fourth-quarter fiscal 2017 revenues on the back of sales growth in the Animal Health, Mineral Nutrition and Performance Products segments.
Here's Why You Should Buy Lantheus Holdings (LNTH) Right Now
by Zacks Equity Research
Lantheus Holdings (LNTH) banks on DEFINITY and TechneLite sales for growth. The company's focus on global expansion is also encouraging.